Novartis: UBS still a buyer
(CercleFinance.com) - UBS reiterates its buy recommendation on Novartis shares, with an unchanged target price of E111, following the announcement of its Q4 2024 results.
This TP gives the stock 16% upside potential.
We are raising core sales and EBIT for 2025-29 by around 3% p.a. following strong Q4 2024 results. We note the strong H1/H2 growth differential in 2025 on patent expiries, UBS says.
For 2025, Novartis expects "mid to high single-digit" growth in sales and "high single-digit to low double-digit" growth in core operating income.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
This TP gives the stock 16% upside potential.
We are raising core sales and EBIT for 2025-29 by around 3% p.a. following strong Q4 2024 results. We note the strong H1/H2 growth differential in 2025 on patent expiries, UBS says.
For 2025, Novartis expects "mid to high single-digit" growth in sales and "high single-digit to low double-digit" growth in core operating income.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.